Positive FDA feedback confirms clear clinical pathway for BX011 targeting S. aureus in Diabetic Foot Infections, building on Company’s prior ...

Positive FDA feedback confirms clear clinical pathway for BX011 targeting S. aureus in Diabetic Foot Infections, building on Company's prior Phase 2 success BiomX expects FDA feedback on BX004 clinica ...

A new review led by Associate Professor Sanjay Singhal from Dr. Ram Manohar Lohia Institute of Medical Sciences sheds light on the prevalence and practice patterns of ADT in patients with ARDS.

Discusses Innovations in Inhaled Treprostinil Therapies and Updates on Drug Delivery Technologies October 28, 2025 2:00 ...

Good morning, everyone. My name is Dina Elmonshed, one of the U.S. biotech analysts here at UBS. And joining me today is the President and CEO of Vertex Pharmaceuticals, Reshma Kewalramani. Thank you ...

Recorded $51.7 million in net product sales of YUTREPIA™ as launch momentum continuesAchieved profitability in the first full quarter of YUTREPIA salesMore than 2,000 unique patient prescriptions and ...

A new review led by Associate Professor Sanjay Singhal from Dr. Ram Manohar Lohia Institute of Medical Sciences sheds light on the prevalence and ...

Jefferies, Piper Sandler, and Guggenheim Securities are acting as joint book-running managers for the offering. Oppenheimer & Co. is acting as the lead manager, and Citizens Capital Markets and H.C.

Judges in the prestigious Digital Health Hub Foundation 2025 Digital Health Awards recognized OMRON Healthcare as the Best in ...

Jefferies, Piper Sandler, and Guggenheim Securities are acting as joint book-running managers for the proposed offering. Oppenheimer & Co. is acting as the lead manager, and Citizens Capital Markets ...

The company will also host a webcast at 8:30 a.m. Eastern Time on November 3, 2025, to review financial performance and provide ... administered twice-daily with a next-generation nebulizer, and ...